Long-term protection from myocardial ischemic events in a randomized trial of brief integrin β3 blockade with percutaneous coronary intervention

JAMA

Volumn 278, Issue 6, 1997, Pages 479-484

  Topol, Eric J ^a   Ferguson, James J ^c   Weisman, Harlan F ^f   Tcheng, James E ^e   Ellis, Stephen G ^a   Kleiman, Neal S ^b   Ivanhoe, Russell J ^d   Wang, Ann L ^f   Miller, David P ^a   Anderson, Keaven M ^f   Califf, Robert M ^e  

^a LERNER RESEARCH INSTITUTE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c TEXAS HEART INSTITUTE   (United States)

^d Florida Heart Group   (United States)

^e DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^f CENTOCOR INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; BETA 3 ADRENERGIC RECEPTOR BLOCKING AGENT; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DILATATION; DEATH; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 8544284052     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.278.6.479     Document Type: Article

References (39)

1. The BARI Investigators. The Bypass Angioplasty Revascularization Investigation (BARI): five year mortality and morbidity in a randomized study comparing CABG and PTCA patients with multivessel coronary disease. N Engl J Med. 1996;335:1217-1225.
2. Popma J, Califf RM, Topol EJ. Clinical trials of restenosis after coronary angioplasty. Circulation. 1991;84:1426-1436.
3. Topol EJ, Ellis SG, Cosgrove DM, et al. Analysis of coronary angioplasty practice in the United States using a private insurance database. Circulation. 1993;87:1489-1497.
4. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med. 1994;331:489-495.
5. Fischman DL, Leon MB, Baim DS, et al, for the Stent Restenosis Study Investigators. A randomized comparison of stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med. 1994;331:496-501.
6. Topol EJ. Caveats about elective coronary stenting. N Engl J Med. 1994;331:539-541.
7. Weintraub WS, Boccuzzi SJ, Klein JL, et al. Lack of effect of lovastatin on restenosis after coronary angioplasty. N Engl J Med. 1994;331:1331-1337.
8. Serruys PW, Klein W, Tijssen JPG, et al. Evaluation of ketanserin in the prevention of restenosis after percutaneous transluminal coronary angioplasty. Circulation. 1993;88:1588-1601.
9. The Multicenter European Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous coronary angioplasty: results of the MERCATOR study: a multicenter, randomized, double-blind, placebo-controlled trial. Circulation. 1992;86:100-110.
10. Hillegass WB, Ohman EM, Califf RM. Restenosis: the clinical issues. In: Topol EJ, ed. Textbook of Interventional Cardiology. 2nd ed. Philadelphia, Pa: WB Saunders Co; 1994:415-435.
11. Herrman JR, Hermans WRM, Vos J, Serruys PW. Pharmacological approaches to the prevention of restenosis following angioplasty. Drugs. 1993;46:259-262.
12. Serruys PW, Rutsch W, Heyndricks GR, et al. Prevention of restenosis after percutaneous transluminal coronary angioplasty with thromboxane A2-receptor blockade: a randomized, double-blind, placebo-controlled trial. Circulation. 1991;84:1568-1580.
13. Leaf A, Jorgensen MB, Jacobs AK, et al. Do fish oils prevent restenosis after coronary angioplasty? Circulation. 1994;90:2248-2257.
14. Serruys PW, Herrman JPR, Simon R, et al. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med. 1995;333:757-763.
15. Topol EJ, Califf RM, Weisman HF, et al, for the EPIC Investigators. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet. 1994;343:881-886.
16. The EPIC Investigators. Prevention of ischemic complications in high-risk angioplasty by a chimeric monoclonal antibody c7E3 Fab fragment directed against the platelet glycoprotein IIb/IIIa receptor. N Engl J Med. 1994;330:956-961.
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
18. Nelson W. Graphical analysis of system repair data. J Qual Technol. 1987;20:24-35.
19. Wong CB, Porter TR, Xie F, Deligonul U. Segmental analysis of coronary arteries with equivalent plaque burden by intravascular ultrasound in patients with and without angiographically significant coronary artery disease. Am J Cardiol. 1995;76:598-603.
20. Abdelmeguid AE, Ellis SG, Sapp SK, Whitlow PL, Topol EJ. Defining the appropriate threshold of creatine kinase elevation after percutaneous coronary interventions. Am Heart J. 1996;131:1097-1105.
21. Abdelmeguid AE, Topol EJ, Whitlow PL, Sapp SK, Ellis SG. Significance of mild transient release of creatine kinase MB fraction after percutaneous interventions. Circulation. 1996;94:1528-1536.
22. Redwood SR, Popma JJ, Kent KM, et al. 'Minor' CPK-MB elevations are associated with increased late mortality following ablative new-device angioplasty in native coronary arteries. Circulation. 1995;92(suppl I):I544. Abstract.
23. Tardiff BE, Califf RM, Tcheng JE, et al, for the IMPACT II Investigators. Post-intervention cardiac enzyme elevations: prognostic significance in IMPACT II. J Am Coll Cardiol. 1996;27(suppl A):A-83A. Abstract.
24. Abdelmeguid AE, Whitlow PL, Sapp SK, Ellis SG, Topol EJ. Long-term outcome of transient, uncomplicated, in-laboratory coronary artery closure. Circulation. 1995;91:2733-2741.
25. Kong TQ, Davidson CJ, Meyers SN, Tauke JT, Parker MA, Bonow RO. Prognostic implication of creatine kinase elevation following elective coronary artery interventions. JAMA. 1997;277:461-466.
26. Coller BS. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet GP IIb/IIIa complex. J Clin Invest. 1985;76:101-108.
27. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med. 1995;332:1553-1559.
28. 3 integrin is necessary for smooth muscle cells to migrate in response to insulin-like growth factor I. Proc Natl Acad Sci U S A. 1996;93:2482-2487.
29. 3 integrin with a small peptide antagonist GpenGRGDSPCA. J Vasc Surg. 1994;19:125-134.
30. 3 (the vitronectin receptor) in a guinea pig model of restenosis. Circulation. 1996;94(suppl):I-517. Abstract.
31. 3 during angiogenesis. J Clin Invest. 1996;98:426-433.
32. Speir E, Modali R, Huang ES, et al. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science. 1994;265:391-394.
33. Zhou YF, Leon MB, Waclawiw MA, et al. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N Engl J Med. 1996;335:624-630.
34. Reverter JC, Beguin S, Kessels H, Kumar R, Hemker HC, Coller BS. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody: potential implications for the effect of c7E3 Fab treatment on acute thrombosis and 'clinical restenosis.' J Clin Invest. 1996;98:863-874.
35. The GUSTO II Angioplasty Substudy Investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator and recombinant hirudin with heparin for acute myocardial infarction. N Engl J Med. 1997;336:1621-1628.
36. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy, 1: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81-106.
37. Latini R, Maggioni AP, Flather M, Sleight P, Tognoni G. ACE inhibitor use in patients with myocardial infarction: summary of evidence from clinical trials. Circulation. 1995;92:3132-3137.
38. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
39. Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction: an overview of results from randomized controlled trials. JAMA. 1988;260:1910-1916.